Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia
- 1 December 2010
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 38 (12) , 1167-1177
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experienceBlood, 2009
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaBlood, 2008
- Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1Molecular Immunology, 2008
- ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemiaBlood, 2008
- From G0 to S phase: A view of the roles played by the retinoblastoma (Rb) family members in the Rb‐E2F pathwayJournal of Cellular Biochemistry, 2007
- CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cellsBlood, 2007
- Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitorBioorganic & Medicinal Chemistry Letters, 2007
- Differential control of G0 programme in chronic lymphocytic leukaemia: a novel prognostic factorBritish Journal of Haematology, 2005
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic LeukemiaJournal of Experimental Medicine, 2001
- Induction of apoptosis in fibroblasts by c-myc proteinCell, 1992